Integer Holdings (ITGR)
(Delayed Data from NYSE)
$131.49 USD
-0.94 (-0.71%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $131.54 +0.05 (0.04%) 7:58 PM ET
4-Sell of 5 4
C Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$131.49 USD
-0.94 (-0.71%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $131.54 +0.05 (0.04%) 7:58 PM ET
4-Sell of 5 4
C Value B Growth C Momentum B VGM
Zacks News
Haemonetics (HAE) Q1 Earnings Top Estimates, 2024 View Up
by Zacks Equity Research
The robust volume growth and price benefits in the Plasma business drive Haemonetics' (HAE) fiscal first-quarter performance.
QIAGEN (QGEN) Receives FDA Approval for AYVAKIT CDX Test
by Zacks Equity Research
QIAGEN's (QGEN) latest approval adds to its leading portfolio in precision medicine, including 12 FDA-approved companion diagnostics.
Inogen (INGN) Q2 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
Despite higher domestic business-to-business sales and rental revenues, Inogen's (INGN) overall second-quarter results reflect soft performances.
Here's Why You Should Invest in Medtronic (MDT) Stock Now
by Zacks Equity Research
Investors are optimistic about Medtronic (MDT) on strong growth prospects within the Neurosurgery portfolio and upbeat 2024 guidance.
OPKO Health (OPK) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall second-quarter results reflect soft performances.
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Q2 Loss
by Zacks Equity Research
Strong testing volume improvement across all businesses drives Myriad Genetics' (MYGN) Q2 performance.
Bio-Rad (BIO) Beats on Q2 Earnings Estimates, Cuts 2023 View
by Zacks Equity Research
Growth across the Life Science portfolio and strong double-digit growth for ddPCR drive Bio-Rad (BIO) Q2 performance.
AMN Healthcare (AMN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) dismal results in all its segments led to a soft overall Q2 performance.
DaVita (DVA) Tops Q2 Earnings Estimates, Ups FY23 EPS View
by Zacks Equity Research
DaVita's (DVA) robust dialysis patient service drives its second-quarter performance.
Teleflex (TFX) Q2 Earnings Top Estimates, 2023 Sales View Up
by Zacks Equity Research
Strong performances in its Vascular, Interventional and Surgical businesses drives Teleflex (TFX) Q2 revenues.
PacBio (PACB) Tops on Q2 Earnings, Raises FY23 Revenue View
by Zacks Equity Research
PacBio (PACB) witnesses strong revenue growth in the second quarter, partly aided by customers' product transition to the Revio system.
Surmodics (SRDX) Q3 Earnings Top Estimates, FY23 View Up
by Zacks Equity Research
Surmodics (SRDX) reports a solid fiscal third quarter top line on the back of robust Medical Device revenues.
BD (BDX) Q3 Earnings Surpass Estimates, Margins Contract
by Zacks Equity Research
BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal third quarter.
Nevro (NVRO) Q2 Earnings Lag Estimates, FY23 View Cut
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in the second quarter owing to robust domestic and international performances.
Inspire Medical (INSP) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the second quarter.
Ecolab (ECL) Q2 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Ecolab's (ECL) robust performance across all segments drives its Q2 sales, despite business challenges.
Integer Holdings (ITGR) Q2 Earnings Top Estimates, FY23 View Up
by Zacks Equity Research
Integer Holdings' (ITGR) second-quarter results reflect robust Medical and Non-Medical Sales, besides strength in all the product lines.
Compared to Estimates, Integer (ITGR) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Integer (ITGR) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Integer (ITGR) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of 15.15% and 8.99%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ITGR or GMED: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ITGR vs. GMED: Which Stock Is the Better Value Option?
Analysts Estimate Hologic (HOLX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Hologic (HOLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Integer (ITGR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Integer Holdings (ITGR) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Integer Holdings' (ITGR) solid foothold in the broader MedTech space.
Here's Why You Should Hold Integer Holdings (ITGR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and a solid foothold in the broader MedTech space.